Breugelmans Tom, Arras Wout, Boen Lauren-Emma, Borms Eliah, Kamperdijk Lisa, De Man Joris, Van de Vijver Els, Van Gils Ann, De Winter Benedicte Y, Moes Nicolette, Smet Annemieke
Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Infla-Med Research Consortium of Excellence, University of Antwerp, Antwerp, Belgium.
Inflamm Bowel Dis. 2023 Apr 3;29(4):589-601. doi: 10.1093/ibd/izac217.
Intestinal mucosal healing is nowadays preferred as the therapeutic endpoint in inflammatory bowel disease (IBD), but objective measurements at the molecular level are lacking. Because dysregulated mucin expression is suggested to be involved in mucosal barrier dysfunction in IBD, we investigated mucin expression in association with barrier mediators and clinical characteristics in colonic tissue of a pediatric IBD population.
In this cross-sectional monocentric study, we quantified messenger RNA (mRNA) expression of mucins, intercellular junctions, and cell polarity complexes in inflamed and noninflamed colonic biopsies from pediatric IBD (n = 29) and non-IBD (n = 15) patients. We then validated mucin expression at protein level and correlated mucin mRNA expression with expression of barrier mediators and clinical data.
The expression of MUC1, MUC3A, MUC4, and MUC13 was increased in the inflamed colon of pediatric IBD patients compared with the noninflamed colon of non-IBD control subjects. Especially MUC13 mRNA expression associated with the expression of barrier mediators, including CDH1, OCLN, and TJP2. MUC1 and MUC3B mRNA expression in combination with calprotectin levels most accurately discriminated IBD patients from non-IBD control subjects (90.6% area under the receiver-operating characteristic curve [AUCROC], 92.0% sensitivity, 73.7% specificity), whereas aberrant mRNA expression of MUC1, MUC3A, MUC4, and MUC13 was distinctive for ulcerative colitis and of MUC3B for Crohn's disease. Furthermore, expression of MUC3A, MUC3B, and MUC4 correlated with clinical disease activity (ie, Pediatric Ulcerative Colitis Activity Index and Pediatric Crohn's Disease Activity Index), and of MUC1, MUC2, MUC4, and MUC13 with endoscopic colitis severity in ulcerative colitis patients.
Colonic mucin expression is disturbed in pediatric IBD patients and associates with disease activity and presentation, suggesting its use as molecular marker to aid in disease diagnosis and management.
如今,肠道黏膜愈合被视为炎症性肠病(IBD)的治疗终点,但缺乏分子水平的客观测量方法。由于黏蛋白表达失调被认为与IBD的黏膜屏障功能障碍有关,我们研究了儿童IBD患者结肠组织中黏蛋白表达与屏障介质及临床特征的关系。
在这项横断面单中心研究中,我们对来自儿童IBD患者(n = 29)和非IBD患者(n = 15)的炎症性和非炎症性结肠活检组织中黏蛋白、细胞间连接和细胞极性复合物的信使核糖核酸(mRNA)表达进行了定量分析。然后,我们在蛋白质水平上验证了黏蛋白的表达,并将黏蛋白mRNA表达与屏障介质的表达及临床数据进行了关联分析。
与非IBD对照受试者的非炎症性结肠相比,儿童IBD患者炎症性结肠中MUC1、MUC3A、MUC4和MUC13的表达增加。特别是MUC13 mRNA表达与包括CDH1、OCLN和TJP2在内的屏障介质的表达相关。MUC1和MUC3B mRNA表达与钙卫蛋白水平相结合,能最准确地区分IBD患者和非IBD对照受试者(受试者操作特征曲线下面积[AUCROC]为90.6%,敏感性为92.0%,特异性为73.7%),而MUC1、MUC3A、MUC4和MUC13的异常mRNA表达在溃疡性结肠炎中具有特异性,MUC3B的异常mRNA表达在克罗恩病中具有特异性。此外,MUC3A、MUC3B和MUC4的表达与临床疾病活动度(即儿童溃疡性结肠炎活动指数和儿童克罗恩病活动指数)相关,MUC1、MUC2、MUC4和MUC13的表达与溃疡性结肠炎患者的内镜下结肠炎严重程度相关。
儿童IBD患者结肠黏蛋白表达紊乱,与疾病活动度和表现相关,提示其可作为分子标志物辅助疾病诊断和管理。